Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 1:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 10,871 matching trials from the live ClinicalTrials.gov search.
Conditions
Short Cervical Length
Interventions
Vaginal progesterone, Placebo, Arabin Pessary
Drug · Device
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
64
States / cities
Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
4,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Hayward, California • Long Beach, California + 28 more
Conditions
Endometrial Cancer
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
68
States / cities
Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more
Conditions
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations
Interventions
Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
Drug
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
21
States / cities
Fullerton, California • Los Angeles, California • Orange, California + 17 more
Conditions
Heart Transplant, Pediatric Heart Transplant, Rejection, Cardiac MRI, Cell Free DNA
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 16 more
Conditions
Early Breast Cancer
Interventions
Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
72
States / cities
Daphne, Alabama • Bakersfield, California • Fullerton, California + 66 more
Conditions
Enterovirus, Rhinovirus
Interventions
Nitazoxanide, Placebo
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years and older
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Hot Springs, Arkansas + 36 more
Conditions
Diabetes Mellitus, Type 2
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Completed No phase listed Observational Results available

TransForm™ Occlusion Balloon Catheter Registry

NCT01949779
Conditions
Intracranial Aneurysms
Interventions
TransForm™ Occlusion Balloon Catheter
Device
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Palm Springs, California • Lexington, Kentucky • Worcester, Massachusetts + 3 more
Conditions
Hypertriglyceridemia, Severe Hypertriglyceridemia
Interventions
ION775
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Lincoln, California • Aurora, Colorado • Boca Raton, Florida + 13 more
Terminated Not applicable Interventional Accepts healthy volunteers

Term Infants Fed a Partially Hydrolyzed Whey Protein-Based Formula

NCT04934397
Conditions
Gastro-Intestinal Tolerance
Interventions
Study Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
7 Days to 65 Days
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Dothan, Alabama • Spring Hill, Florida • Idaho Falls, Idaho + 9 more
Conditions
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Interventions
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
Drug
Lead sponsor
CARGO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
Active, not recruiting Not applicable Interventional Results available

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

NCT03635424
Conditions
Bicuspid Aortic Valve
Interventions
Medtronic TAVR Systems
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Thousand Oaks, California + 21 more
Conditions
Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Fludarabine, KITE-222
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Stanford, California • Tampa, Florida • St Louis, Missouri + 4 more
Conditions
Postpartum Pelvic Floor Function and Symptoms
Interventions
Digital therapeutic motion-based device
Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Conditions
Physical Fitness
Interventions
Balanced Progressive Intensity Training (BPIT) 5-Line Method
Behavioral
Lead sponsor
MMSx Authority Institute for Movement Mechanics & Biomechanics Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Columbus, Ohio • Powell, Ohio
Conditions
Medulloblastoma
Interventions
Lomustine, Vincristine, Cisplatin, Cyclophosphamide, Mesna
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
3 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Aurora, Colorado • Orlando, Florida + 13 more
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more
Conditions
Crohn's Disease
Interventions
SL-325, Placebo
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
20
States / cities
Little Rock, Arkansas • Oxnard, California • Temple City, California + 17 more
Conditions
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions
Tovaxin
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
742
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer
Interventions
trastuzumab, paclitaxel, recombinant interleukin-12
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio